Margarida Brito

Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer.

Francisco Branco, Duarte Machado, Filipa F Silva et al. · PubMed · 2019 · 43 citations · Full text

High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: Data from regional cervical cancer screening program

Hugo Sousa, Ana Tavares, Carla Cristian Campos et al. · Papillomavirus Research · 2019 · 30 citations · Full text

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

Ben Tran, José Manuel Ruiz-Morales, Enrique González‐Billalabeitia et al. · Cancer Medicine · 2019 · 25 citations · Full text

Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study

Margarida Brito, Susana Esteves, R André et al. · Supportive Care in Cancer · 2015 · 23 citations

Breast Oncology, Oncology, Cancer Epidemiology +13

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

Christian D. Fankhauser, Ben Tran, Manuel Pedregal et al. · European Urology Focus · 2020 · 20 citations · Full text

Prophylactic Anticoagulation, Risk-benefit Analysis, Medicine +6